CeriBell, Inc. filings document the regulatory record of a medical technology company commercializing point-of-care EEG systems for neurological monitoring. Its Form 8-K reports include furnished financial results, FDA clearance events for the Clarity seizure-detection algorithm and other Ceribell System indications, and material agreements related to facility leases and headband supply arrangements.
The company’s proxy materials and governance filings cover annual meeting matters, board composition, committee assignments, director compensation arrangements, indemnification agreements, and related shareholder voting procedures. These disclosures provide formal records of Ceribell’s operating updates, governance structure, contractual obligations, and public-company reporting events.
CeriBell, Inc. is a medical technology company focused on point-of-care EEG for critically ill patients, using AI-powered algorithms to detect seizures, delirium and other serious neurological conditions. Its Ceribell System combines disposable headbands or headcaps, a pocket-sized recorder and a cloud portal for real-time monitoring.
As of December 31, 2025, the system had been adopted by more than 600 U.S. hospitals, targeting a U.S. addressable market it estimates at over $3.5 billion when including seizures and delirium. In 2025 CeriBell generated $89.1 million in revenue, up from $65.4 million in 2024, with a gross margin of 88% and a net loss of $53.4 million.
Growth is supported by expanding clinical indications: FDA 510(k) clearance for its Clarity algorithm to diagnose electrographic status epilepticus in adults and for delirium monitoring, plus Breakthrough Device Designation for an in‑development large vessel occlusion stroke detection solution. The company relies on recurring revenue from single-use Wearables and subscriptions to its software and hardware platform.
Ceribell, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining loss-making. Fourth quarter revenue rose 34% to $24.8 million, with product revenue up 33% and subscription revenue up 37%. Gross margin was a high 87%, but operating expenses increased 24% to $36.2 million, leading to a net loss of $13.5 million, or $0.36 per share.
For full year 2025, revenue grew 36% to $89.1 million, driven by both product and subscription sales. Gross profit reached $78.3 million with an improved gross margin of 88%, but operating expenses rose 42% to $136.7 million, resulting in a net loss of $53.4 million, or $1.46 per share. Ceribell ended the year with $159.3 million in cash, cash equivalents, and marketable securities and 647 active accounts.
The company highlighted multiple regulatory milestones, including two FDA 510(k) clearances and an FDA Breakthrough Device Designation, and guided 2026 revenue to $111–115 million, implying about 25–29% growth over 2025.
Ceribell, Inc. (CBLL) officer David J. Foehr reported a proposed sale of 781 common shares, with an aggregate market value of $15,604.38 and an approximate sale date of February 24, 2026. The shares came from restricted stock vesting from the issuer on February 20, 2026, as compensation. The proposed sale is accompanied by a September 4, 2025 date for adoption of a Rule 10b5-1 plan or giving of an instruction. In the preceding three months, Foehr reported sales of 5,265 shares on December 3, 2025; 5,556 on January 5, 2026; 5,556 on February 3, 2026; and 569 on February 23, 2026.
Ceribell, Inc. (CBLL) officer Raymond Woo reported a proposed sale of 705 common shares, with an aggregate market value of $13,955.12 and an approximate sale date of February 23, 2026. He acquired the shares from the issuer as compensation through restricted stock vesting on February 20, 2026; the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution. The notice lists three prior sales of 11,112 shares each: December 1, 2025, for $184,424.30; January 2, 2026, for $235,228.09; and February 2, 2026, for $231,129.60 in gross proceeds.
Xingjuan Chao, an officer and director of Ceribell, Inc. (CBLL), reported a proposed sale of 2,084 common shares with an aggregate market value of $41,251.74 and an approximate sale date of February 23, 2026. The shares were acquired from the issuer through restricted stock vesting on February 20, 2026. The notice says the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution. It also lists prior sales of 79,000 shares on January 5, 2026, for gross proceeds of $1,680,124.43, and 39,000 shares on February 4, 2026, for gross proceeds of $786,392.36.
Ceribell, Inc. officer Scott E. Blumberg reported a proposed sale of 808 common shares, with an aggregate market value of $15,993.96 and an approximate sale date of February 23, 2026. He acquired the shares through restricted stock vesting on February 20, 2026, as compensation. The remarks state that the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution. During the prior three months, Blumberg reported sales of 36,000 common shares on December 22, 2025, for gross proceeds of $756,000.
Ceribell, Inc. officer David J. Foehr reported a proposed sale of 569 common shares, with an aggregate market value of $11,263.07 and an approximate sale date of February 23, 2026. The shares were acquired through restricted stock vesting on February 20, 2026. Remarks state that the sale includes an amount necessary to cover a tax obligation resulting from settlement of a vested equity award distribution.
Ceribell, Inc. director Josef Parvizi, through the Josef Parvizi Trust, sold 16,714 shares of common stock in open-market transactions on February 19, 2026 under a Rule 10b5-1 trading plan adopted on August 18, 2025.
The weighted average sale price was $20.27 per share, with individual trades between $20.00 and $20.77. Following the sale, the Josef Parvizi Trust held 722,652 shares. Separate Innovation ACP Trust and ACP 2021 Trust holdings were 907,911 and 369,088 shares, respectively, where Parvizi is a co-trustee and may be deemed to share beneficial ownership but disclaims it except to the extent of his pecuniary interest.
Ceribell, Inc. director Josef Parvizi reported automatic sales of common stock through trusts associated with him. A total of 8,286 shares were sold in open-market transactions at a weighted average price of about $20 per share under a Rule 10b5-1 trading plan adopted on August 18, 2025. The Josef Parvizi Trust now holds 739,366 shares indirectly, while the Innovation ACP Trust and ACP 2021 Trust hold 907,911 and 369,088 shares indirectly, respectively.